"[A] small drug molecule called BX795, which is sold to labs for use in experiments, helped clear HSV-1 infection in cultured human corneal cells, in donated human corneas, and in the corneas of mice infected with HSV-1. [...] Additionally, the concentration of BX795 needed to clear HSV-1 infection is quite low. We saw clearance of the virus at concentrations of BX795 that were five times lower than concentrations of antiviral compounds in available nucleoside analogs, Shukla said. [...] Because BX795 targets a common pathway that many viruses use to replicate inside the cell, it could be a new kind of broad-spectrum antiviral that might be used to treat other viral infections. [...] Because of BX795's low toxicity, it has a great potential for systemic use as well as topical application."
https://www.sciencedaily.com/releases/2018/02/180215110339.htm
https://www.sciencedaily.com/releases/2018/02/180215110339.htm